Joohyuk Sohn

home / authors / joohyuk-sohn

Articles

30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

Aarti Chawla;Komal Jhaveri;Patrick Neven, MD, PhD;Monica Lis Casalnuovo;Sung-Bae Kim;Eriko Tokunaga;Philippe Aftimos;Cristina Saura;Joyce A. O’Shaughnessy;Nadia Harbeck, MD, PhD;Lisa A. Carey, MD;Guiseppe Curigliano;Antonio Llombart-Cussac;Elgene Lim, MBBS, FRACP, PhD;María de la Luz García Tinoco;Joohyuk Sohn;Andre Mattar;Qingyuan Zhang;Chiun-Sheng Huang;Chih-Chiang Hung;Jorge Luis Martinez Rodriguez;Manuel Ruiz Borrego
June 16th 2025
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

Matthew P. Goetz, MD;Masakazu Toi;Jens Huober, MD;Joohyuk Sohn;Oliver Trédan;In Hae Park;Mario Campone;Shin-Cheh Chen;Luis Manuel Manso;Shani Paluch-Shimon;Orit C. Freedman;Joyce A. O’Shaughnessy;Xavier Pivot;Sara M. Tolaney, MD, MPH;Sara A. Hurvitz, MD;Antonio Llombart;Valérie André;Abhijoy Saha;Gertjan van Hal;Ashwin Shahir;Hiroji Iwata;Stephen R.D. Johnston
June 23rd 2024

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: July 1st 2025
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes